Tiziana Life Sciences (NASDAQ:TLSA) Shares Down 3.2% – Here’s Why

Tiziana Life Sciences Ltd (NASDAQ:TLSA) traded down 3.2% during trading on Monday . The company traded as low as $1.5103 and last traded at $1.53. 113,997 shares changed hands during trading, a decline of 30% from the average session volume of 163,390 shares. The stock had previously closed at $1.58.

Analysts Set New Price Targets

Several research firms recently issued reports on TLSA. Wall Street Zen cut shares of Tiziana Life Sciences from a “hold” rating to a “sell” rating in a research report on Saturday, April 18th. Weiss Ratings raised shares of Tiziana Life Sciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, May 6th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Tiziana Life Sciences currently has an average rating of “Sell”.

Tiziana Life Sciences Price Performance

The stock has a fifty day moving average of $1.31 and a two-hundred day moving average of $1.50.

Tiziana Life Sciences (NASDAQ:TLSA) last released its quarterly earnings data on Friday, May 1st. The company reported ($0.28) EPS for the quarter.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Cubist Systematic Strategies LLC purchased a new stake in Tiziana Life Sciences during the first quarter worth approximately $25,000. Rachor Investment Advisory Services LLC purchased a new position in shares of Tiziana Life Sciences in the 4th quarter valued at $25,000. Bison Wealth LLC acquired a new position in shares of Tiziana Life Sciences during the 4th quarter valued at $30,000. HRT Financial LP acquired a new position in shares of Tiziana Life Sciences during the 4th quarter valued at $36,000. Finally, Marshall Wace LLP purchased a new stake in Tiziana Life Sciences during the 2nd quarter worth $39,000.

About Tiziana Life Sciences

Tiziana Life Sciences plc (NASDAQ: TLSA) is a clinical-stage biotechnology company focused on the development of novel therapeutics in the fields of oncology, immunology and infectious diseases. Headquartered in London, with research and development operations in Cambridge, Massachusetts, the company advances both small-molecule inhibitors and monoclonal antibody candidates designed to modulate immune pathways and target tumor growth.

The company’s lead small?molecule program, milciclib, is an oral cyclin?dependent kinase inhibitor currently in Phase II clinical trials for hepatocellular carcinoma and certain neuroendocrine tumors.